<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0404245151
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2024
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Nyvepria
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        PEGFILGRASTIM
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Subcutaneous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Pre-filled syringe
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Controlled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        Store in a refrigerator (2°C – 8°C), do not freeze
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        1765.65
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="HOSPIRA ZAGREB D.O.O." />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            HOSPIRA ZAGREB D.O.O.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2657]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Pfizer Saudi Trading
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Pfizer Europe MA EEIG
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L03AA13
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Nyvepria contains the active substance pegfilgrastim. It is used in patients treated with cytotoxic chemotherapy (medicines that destroy rapidly growing cells) to reduce the duration of neutropenia (low neutrophil count, a type of white blood cell) and to help prevent febrile neutropenia (low white blood cell count with a fever). Nyvepria is for use in adults aged 18 years and over.</p><p>&nbsp;</p><p>White blood cells are important for fighting off infection. If the white blood cell count to fall too low, due to your cytotoxic chemotherapy, your body may not be able to fight off microorganisms and this will increase the chances of an infection. Pegfilgrastim, is very similar to a natural protein in the body called granulocyte colony stimulating factor and it works by encouraging your bone marrow to produce more white blood cells that help your body fight off infections.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use Nyvepria </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to pegfilgrastim, filgrastim, or any of the other ingredients of this medicine (listed in section&nbsp;6).</p><p><strong>&nbsp;</strong></p><p><strong>Warnings and precautions </strong></p><p>&nbsp;</p><p>Talk to your doctor, pharmacist or nurse before using Nyvepria:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have recently had a serious lung infection (pneumonia), fluid in the lungs (pulmonary oedema), inflammation of the lungs (interstitial lung disease), or an abnormal chest x‑ray (lung infiltration).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are aware of any altered blood cell counts (e.g. increase in white blood cells or anaemia) or decreased blood platelet counts (thrombocytopenia), which reduces the ability of your blood to clot. Your doctor may want to monitor you more closely.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have sickle cell anaemia. Your doctor may monitor your condition more closely.</p><p>&nbsp;</p><p>Talk to your doctor, pharmacist or nurse while using Nyvepria:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are a patient with breast cancer or lung cancer, pegfilgrastim in combination with chemotherapy and/or radiation therapy may increase your risk of a precancerous blood condition called myelodysplastic syndrome (MDS) or a blood cancer called acute myeloid leukaemia (AML). Symptoms may include tiredness, fever, and easy bruising or bleeding.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you get an allergic reaction including weakness, drop in blood pressure, difficulty breathing, swelling of the face, lips, tongue or other parts of the body (anaphylaxis), redness and flushing, skin rash or hives on the skin and areas of the skin that itch.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you get a cough or fever, and have difficulty breathing. This can be a sign of acute respiratory distress syndrome (ARDS).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have any of the following side effects:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling or puffiness, passing urine less frequently, difficulty breathing, abdominal (belly) swelling and feeling of fullness, and a general feeling of tiredness.</p><p>These could be symptoms of condition called capillary leak syndrome which causes blood to leak from the small blood vessels into your body. See section&nbsp;4.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you get left upper abdominal pain or pain at the tip of your shoulder. This may be a sign of a problem with your spleen (splenomegaly).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you get fever, abdominal pain, malaise, and back pain as these may be symptoms of inflammation of the aorta (the large blood vessel which transports blood from the heart to the body). This disorder can occur rarely in cancer patients and healthy donors.</p><p>&nbsp;</p><p>Your doctor will check your blood and urine regularly as Nyvepria can damage your kidneys (glomerulonephritis).</p><p>&nbsp;</p><p>Severe skin reactions (Stevens-Johnson syndrome; a skin condition that causes painful blisters and sores of the skin and mucous membranes, especially in the mouth) have been reported with the use of pegfilgrastim. Stop using Nyvepria and get medical attention immediately if you notice any of these symptoms: reddish target like or circular patches often with central blisters on the trunk, skin peeling, ulcers of mouth, throat, nose, genitals and eyes possibly with fever and flu-like symptoms beforehand. See section&nbsp;4.</p><p>&nbsp;</p><p>You should talk to your doctor about your risks of developing cancers of the blood. If you have a cancer of the blood or have been told by your doctor that you are at risk of one, you should not use Nyvepria, unless instructed by your doctor.</p><p>&nbsp;</p><p><strong>Loss of response to pegfilgrastim </strong></p><p>If pegfilgrastim treatment does not work or stops working, your doctor will investigate why this has happened including whether you have developed antibodies which neutralise pegfilgrastim&rsquo;s activity.</p><p>&nbsp;</p><p><strong>Children and adolescents</strong></p><p>Nyvepria is not recommended for use in children and adolescents because there is insufficient information on its safety and effectiveness.</p><p>&nbsp;</p><p><strong>Other medicines and Nyvepria </strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p>&nbsp;</p><p><strong>Pregnancy and breast‑feeding </strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p>&nbsp;</p><p>Nyvepria has not been studied in pregnant women. Therefore, your doctor may decide that you should not use this medicine.</p><p>&nbsp;</p><p>If you become pregnant during Nyvepria treatment, speak with your doctor.</p><p>&nbsp;</p><p>Unless your doctor tells you otherwise, you must stop breast‑feeding if you use Nyvepria.</p><p>&nbsp;</p><p><strong>Driving and using machines </strong></p><p>Nyvepria has no or negligible effect on the ability to drive or use machines.</p><p>&nbsp;</p><p><strong>Nyvepria contains sorbitol and sodium </strong></p><p>This medicine contains 30&nbsp;mg sorbitol in each pre-filled syringe which is equivalent to 50&nbsp;mg/mL. The additive effect of concomitantly administered medicines containing sorbitol (or fructose) and dietary intake of sorbitol (or fructose) should be taken into account.</p><p>&nbsp;</p><p>This medicine contains less than 1&nbsp;mmol sodium (23&nbsp;mg) per 6&nbsp;mg dose, that is to say essentially &lsquo;sodium‑free&rsquo;.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Nyvepria is for use in adults aged 18&nbsp;years and over.</p><p>&nbsp;</p><p>Always use this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.</p><p>&nbsp;</p><p>The recommended dose is one 6&nbsp;mg subcutaneous injection (injection under your skin) using a pre‑filled syringe and it should be given at least 24&nbsp;hours after your last dose of chemotherapy at the end of each chemotherapy cycle.</p><p>&nbsp;</p><p><strong>Injecting Nyvepria yourself </strong></p><p>Your doctor may decide that you can inject Nyvepria yourself. Your doctor or nurse will show you how to inject it yourself. Do not try to inject it yourself if you have not been trained.</p><p>&nbsp;</p><p>For instructions on how to inject Nyvepria, read the section at the end of this leaflet.</p><p>&nbsp;</p><p>Do not shake Nyvepria vigorously as this may affect its activity.</p><p>&nbsp;</p><p><strong>If you use more Nyvepria than you should </strong></p><p>If you use more Nyvepria than you should contact your doctor, pharmacist or nurse for advice.</p><p>&nbsp;</p><p><strong>If you forget to inject Nyvepria </strong></p><p>If you have forgotten a dose of Nyvepria, contact your doctor to discuss when you should inject the next dose.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Nyvepria is for use in adults aged 18&nbsp;years and over.</p><p>&nbsp;</p><p>Always use this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.</p><p>&nbsp;</p><p>The recommended dose is one 6&nbsp;mg subcutaneous injection (injection under your skin) using a pre‑filled syringe and it should be given at least 24&nbsp;hours after your last dose of chemotherapy at the end of each chemotherapy cycle.</p><p>&nbsp;</p><p><strong>Injecting Nyvepria yourself </strong></p><p>Your doctor may decide that you can inject Nyvepria yourself. Your doctor or nurse will show you how to inject it yourself. Do not try to inject it yourself if you have not been trained.</p><p>&nbsp;</p><p>For instructions on how to inject Nyvepria, read the section at the end of this leaflet.</p><p>&nbsp;</p><p>Do not shake Nyvepria vigorously as this may affect its activity.</p><p>&nbsp;</p><p><strong>If you use more Nyvepria than you should </strong></p><p>If you use more Nyvepria than you should contact your doctor, pharmacist or nurse for advice.</p><p>&nbsp;</p><p><strong>If you forget to inject Nyvepria </strong></p><p>If you have forgotten a dose of Nyvepria, contact your doctor to discuss when you should inject the next dose.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the carton and on the syringe label after EXP. The expiry date refers to the last day of that month.<br /><br /><br />Shelf life: 3 years.</p><p>&nbsp;</p><p>Store in a refrigerator (2&deg;C&nbsp;to&nbsp;8&deg;C).</p><p>&nbsp;</p><p>You may take Nyvepria out of the refrigerator and keep it at room temperature (not above 25&deg;C) for no longer than 15&nbsp;days. Once a syringe has been removed from the refrigerator and has reached room temperature (not above 25&deg;C) it must either be used within 15&nbsp;days or disposed of.</p><p>&nbsp;</p><p>Do not freeze. Nyvepria may be used if it is accidentally frozen for a single period of less than 24&nbsp;hours.</p><p>&nbsp;</p><p>Keep the container in the outer carton in order to protect from light.</p><p>&nbsp;</p><p>Do not use this medicine if you notice it is cloudy or there are particles in it.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is pegfilgrastim. Each pre‑filled syringe contains 6&nbsp;mg of pegfilgrastim in 0.6&nbsp;mL of solution.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are sodium acetate trihydrate, glacial acetic acid, sorbitol, polysorbate&nbsp;20 and water for injections (see section&nbsp;2 &ldquo;Nyvepria contains sorbitol and sodium acetate&rdquo;).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Nyvepria is a clear, colourless, free from visible particles, solution for injection in a pre filled syringe (6 mg/0.6 mL). 

Each pack contains 1 glass pre filled syringe with an attached stainless steel needle, needle cover and an automatic needle guard. 

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder</strong></p><p>Pfizer Europe MA EEIG</p><p>Boulevard de la Plaine 17</p><p>1050 Bruxelles</p><p>Belgium</p><p>&nbsp;</p><p><strong>Manufacturer</strong></p><p>Hospira Zagreb d.o.o.</p><p>Prudnička cesta 60</p><p>10291 Prigorje Brdovečko</p><p>Croatia</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                October 2021
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>&nbsp;</p><p dir="RTL">يحتوي نيفبريا على المادة الفعالة بيجفيلجراستيم. وهو يُستخدم مع المرضى الذين عولجوا بالعلاج الكيميائي السام للخلايا (الأدوية التي تدمر الخلايا سريعة النمو) لتقليل مدة الإصابة بقلة العدلات (انخفاض تعداد العدلات، أحد أنواع خلايا الدم البيضاء) وللمساعدة في منع الإصابة بقلة العدلات الحموية (انخفاض تعداد خلايا الدم البيضاء المصحوب بحمى). ويُخصص نيفبريا للاستخدام مع البالغين من سن ۱۸ عامًا وأكثر.</p><p>&nbsp;</p><p dir="RTL">تُعد خلايا الدم البيضاء مهمة لمحاربة العدوى. وإذا انخفض تعداد خلايا الدم البيضاء بشكل كبير، بسبب خضوعك للعلاج الكيميائي السام للخلايا، فقد لا يتمكن جسمك من محاربة الكائنات الحية الدقيقة وهذا سيزيد من فرص الإصابة بعدوى. إن بيجفيلجراستيم شديد الشبه بأحد البروتينات الطبيعية الموجودة في الجسم، يسمى عامل تحفيز مستعمرات الخلايا المحببة، ويعمل عن طريق حث نخاع العظام على إنتاج المزيد من خلايا الدم البيضاء التي تساعد جسمك على محاربة حالات العدوى.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>موانع استعمال نيفبريا</strong><strong> </strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من الحساسية تجاه بيجفيلجراستيم أو فيلجراستيم أو تجاه أي من المكونات الأخرى لهذا الدواء (المدرجة في القسم ٦).</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>الاحتياطات عند استعمال نيفبريا</strong><strong> </strong></p><p>&nbsp;</p><p dir="RTL">تحدث إلى طبيبك أو الصيدلي أو الممرضة قبل استخدام نيفبريا:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد عانيت مؤخرًا من عدوى رئوية خطيرة (الالتهاب الرئوي) أو تراكم سوائل في الرئتين (التورم الرئوي) أو التهاب الرئتين (داء الرئة الخلالي) أو حصلت على نتيجة غير طبيعية عند خضوعك لفحص أشعة سينية على الصدر (الارتشاح الرئوي).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت على دراية بوجود أي تغيرات في تعدادات خلايا الدم (على سبيل المثال، زيادة في عدد خلايا الدم البيضاء أو فقر الدم) أو بانخفاض تعدادات الصفيحات الدموية (قلة الصفيحات)، مما يقلل من قدرة دمك على التخثر. فقد يرغب طبيبك في مراقبتك عن كثب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من فقر الدم المنجلي. فقد يراقب طبيبك حالتك عن كثب.</p><p>&nbsp;</p><p dir="RTL">تحدث إلى طبيبك أو الصيدلي أو الممرضة أثناء استخدام نيفبريا:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مريضًا مصابًا بسرطان الثدي أو سرطان الرئة، فقد يؤدي استخدام بيجفيلجراستيم بالتزامن مع العلاج الكيميائي و/أو العلاج الإشعاعي إلى زيادة خطر الإصابة بحالة دم محتملة التسرطن تسمى متلازمة خلل التنسج النقوي (MDS) أو سرطان الدم المسمى ابيضاض الدم النقوي الحاد (AML). قد تتضمن الأعراض التعب والحمى وسهولة التكدم أو النزيف.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا أصبت بتفاعل حساسية بما في ذلك الضعف، وانخفاض ضغط الدم، وصعوبة التنفس، وتورم الوجه أو الشفتين أو اللسان أو أجزاء أخرى من الجسم (التأق)، والتورد والاحمرار، وظهور الطفح الجلدي أو الشرى على الجلد، والمناطق الجلدية المسببة للحكة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا أصبت بسعال أو حمى، وكنت تعاني من صعوبة في التنفس. فقد تكون هذه علامة على الإصابة بمتلازمة الضائقة التنفسية الحادة (ARDS).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا أصبت بأي من الأعراض الجانبية التالية:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التورم أو الانتفاخ، وانخفاض معدل التبول، وصعوبة التنفس، وتورم البطن (المعدة) والشعور بالامتلاء، وشعور عام بالتعب.</p><p dir="RTL">حيث يمكن أن تكون هذه أعراض حالة تُسمى متلازمة التسرب الشعيري، وهي تتسبب في تسرّب الدم من الأوعية الدموية الصغيرة إلى جسمك. انظر القسم ٤.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا أصبت بألم في الجزء العلوي الأيسر من البطن أو بألم في طرف كتفك. فقد تكون هذه علامة على وجود مشكلة بطحالك (تضخم الطحال).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا أصبت بالحمى وألم البطن والتوعك وألم الظهر حيث قد تكون هذه أعراضًا لالتهاب الشريان الأبهر (الوعاء الدموي الكبير الذي ينقل الدم من القلب إلى الجسم). نادرًا ما يحدث هذا الاضطراب في مرضى السرطان والمتبرعين الأصحاء.</p><p>&nbsp;</p><p dir="RTL">سيفحص طبيبك دمك وبولك بصورة منتظمة لأن نيفبريا يمكنه أن يسبب تلفًا في كليتيك (التهاب كبيبات الكلى).</p><p>&nbsp;</p><p dir="RTL">تم الإبلاغ عن حدوث تفاعلات جلدية شديدة (متلازمة ستيفنز-جونسون؛ حالة جلدية تسبب بثورًا وتقرحات مؤلمة تصيب الجلد والأغشية المخاطية، خاصةً في الفم) مع استخدام بيجفيلجراستيم. توقف عن استخدام نيفبريا واِسع للحصول على رعاية طبية على الفور إذا لاحظت أيًا من هذه الأعراض: بقع ضاربة إلى الحمرة تشبه دائرة التصويب أو بقع دائرية غالبًا ما توجد بثور في منتصفها تنتشر على الجذع، تقشر الجلد، قرح الفم والحلق والأنف والأعضاء التناسلية والعينين وعلى الأرجح تكون مسبوقة بالحمى وأعراض شبيهة بأعراض الإنفلونزا. انظر القسم ٤.</p><p>&nbsp;</p><p dir="RTL">ينبغي لك التحدث مع طبيبك عن معدلات خطر إصابتك بسرطانات الدم. أما إذا كنت مصابًا بأحد أنواع سرطان الدم أو أخبرك طبيبك أنك معرض لخطر الإصابة بأحدها، ينبغي ألا تستخدم نيفبريا، إلا إذا وجّهك طبيبك لفعل ذلك.</p><p>&nbsp;</p><p dir="RTL"><strong>فقدان الاستجابة لبيجفيلجراستيم</strong><strong> </strong></p><p dir="RTL">إذا لم يُعطي بيجفيلجراستيم مفعولًا أو توقف مفعوله، فسيقوم طبيبك بالبحث في سبب حدوث ذلك بما في ذلك ما إذا كانت قد تكوَّنت لديك أجسام مضادة تبطل نشاط بيجفيلجراستيم.</p><p>&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">لا ينصح باستخدام نيفبريا مع الأطفال والمراهقين بسبب عدم توفر معلومات كافية عن سلامته وفعاليته.</p><p>&nbsp;</p><p dir="RTL"><strong>التداخلات الدوائية مع أخذ هذا المستحضر مع أي أدوية أخرى أو أعشاب أو مكملات غذائية</strong><strong> </strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتناول، أو تناولت مؤخرًا، أو قد تتناول أي أدوية أخرى.</p><p>&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة</strong><strong> </strong></p><p dir="RTL">إذا كنتِ حاملًا أو ترضعين رضاعة طبيعية، أو تعتقدين أنكِ ربما تكونين حاملًا، أو تخططين للإنجاب، فاستشيري طبيبكِ أو الصيدلي قبل تلقي هذا الدواء.</p><p>&nbsp;</p><p dir="RTL">لم تتم دراسة استخدام نيفبريا مع السيدات الحوامل. لذلك، قد يقرر طبيبكِ أنه ينبغي لكِ عدم استخدام هذا الدواء.</p><p>&nbsp;</p><p dir="RTL">إذا أصبحتِ حاملًا أثناء العلاج بنيفبريا، فتحدثي مع طبيبكِ.</p><p>&nbsp;</p><p dir="RTL">يجب عليكِ إيقاف الرضاعة الطبيعية إذا كنتِ تستخدمين نيفبريا، ما لم يخبركِ طبيبكِ بخلاف ذلك.</p><p>&nbsp;</p><p dir="RTL"><strong>تأثير نيفبريا على القيادة واستخدام الآلات</strong><strong> </strong></p><p dir="RTL">نيفبريا ليس له أي تأثير على القدرة على القيادة واستخدام الآلات أو له تأثير لا يكاد يُذكر.</p><p>&nbsp;</p><p dir="RTL"><strong>معلومات هامة حول بعض مكونات نيفبريا</strong></p><p dir="RTL"><br /><strong>يحتوي نيفبريا على السوربيتول (</strong><strong>E420</strong><strong>) والصوديوم</strong><strong> </strong></p><p dir="RTL">يحتوي هذا الدواء على ۳۰ ملجم من السوربيتول في كل محقنة مسبقة التعبئة وهو ما يُعادل ٥۰ ملجم/مل. يجب أن يؤخذ في الاعتبار التأثير الإضافي للأدوية المعطاة بالتزامن التي تحتوي على السوربيتول (أو الفركتوز) والمدخول الغذائي من السوربيتول (أو الفركتوز).</p><p>&nbsp;</p><p dir="RTL">يحتوي هذا الدواء على أقل من ۱ مليمول من الصوديوم (٢٣ ملجم) لكل جرعة قدرها ٦ ملجم، أي أنه يُعد &quot;خاليًا من الصوديوم&quot; بشكل أساسي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">نيفبريا مخصص للاستخدام مع البالغين من سن ۱۸ عامًا وأكثر.</p><p>&nbsp;</p><p dir="RTL">احرص دائمًا على استخدام هذا الدواء تمامًا كما أخبرك طبيبك. وارجع إلى طبيبك أو الصيدلي إذا لم تكن متأكدًا مما ينبغي لك فعله.</p><p>&nbsp;</p><p dir="RTL">الجرعة الموصى بها هي حقنة واحدة تحت الجلد تبلغ ٦ ملجم تُعطى باستخدام محقنة مسبقة التعبئة وينبغي إعطاؤها بعد ۲٤ ساعة على الأقل من تلقي جرعتك الأخيرة من العلاج الكيميائي في نهاية كل دورة علاج كيميائي.</p><p>&nbsp;</p><p dir="RTL"><strong>حقْن نيفبريا بنفسك</strong><strong> </strong></p><p dir="RTL">قد يقرر طبيبك أنه يمكنك حقن نيفبريا بنفسك. وسيوضح لك طبيبك أو الممرضة كيفية حقنه بنفسك. لا تحاول إجراء الحقن بنفسك إذا لم تكن قد تدربت على ذلك.</p><p>&nbsp;</p><p dir="RTL">للحصول على تعليمات حول كيفية حقن نيفبريا، اقرأ القسم الموجود في نهاية هذه النشرة.</p><p>&nbsp;</p><p dir="RTL">لا ترج نيفبريا بقوة حيث إن ذلك قد يؤثر على فعاليته.</p><p>&nbsp;</p><p dir="RTL"><strong>الجرعة الزائدة من نيفبريا</strong><strong> </strong></p><p dir="RTL">إذا استخدمت كمية أكبر مما ينبغي من نيفبريا، فاستشر طبيبك أو الصيدلي أو الممرضة.</p><p>&nbsp;</p><p dir="RTL"><strong>نسيان تناول جرعة نيفبريا</strong><strong> </strong></p><p dir="RTL">إذا كنت قد نسيت أن تتلقى إحدى جرعات نيفبريا، فتواصل مع طبيبك لمناقشة متى ينبغي لك حقن الجرعة التالية.</p><p>&nbsp;</p><p dir="RTL">إذا كانت لديك أي أسئلة إضافية حول استخدام هذا الدواء، فاسأل طبيبك أو الصيدلي أو الممرضة.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كما هو الحال بالنسبة لجميع الأدوية، يمكن أن يسبب هذا الدواء أعراضًا جانبية، غير أنها لا تصيب الجميع.</p><p>&nbsp;</p><p dir="RTL">أخبر طبيبك على الفور إذا أصبت بأي من الأعراض الجانبية التالية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التورم أو الانتفاخ، وانخفاض معدل التبول، وصعوبة التنفس، وتورم البطن (المعدة) والشعور بالامتلاء، وشعور عام بالتعب. عادةً ما تتطور هذه الأعراض بسرعة.</p><p>&nbsp;</p><p dir="RTL">يمكن أن تكون هذه أعراض حالة غير شائعة (قد تصيب ما يصل إلى شخص واحد من بين كل ۱۰۰ شخص) تسمى متلازمة التسرب الشعيري، وهي تتسبب في تسرّب الدم من الأوعية الدموية الصغيرة إلى جسمك وتستلزم علاجًا عاجلًا.</p><p>&nbsp;</p><p dir="RTL"><u>شائعة جدًا: قد تصيب أكثر من شخص واحد من بين كل ۱۰ أشخاص</u></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم بالعظام. سيخبرك طبيبك بما يمكنك تناوله لتخفيف ألم العظام.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الغثيان والصداع.</p><p>&nbsp;</p><p dir="RTL"><u>شائعة: قد تصيب ما يصل إلى شخص واحد من بين كل ۱۰ أشخاص</u></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في موضع الحقن.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أوجاع وآلام عامة في المفاصل والعضلات.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تحدث بعض التغيرات في دمك، ولكن سيتم الكشف عنها عن طريق فحوصات الدم الروتينية. فقد يرتفع تعداد خلايا الدم البيضاء في جسمك لفترة قصيرة. وقد ينخفض تعداد الصفيحات الدموية لديك مما قد يؤدي إلى الإصابة بالتكدم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في الصدر غير ذي صلة باضطرابات القلب.</p><p>&nbsp;</p><p dir="RTL"><u>غير شائعة: قد تصيب ما يصل إلى شخص واحد من بين كل ۱۰۰ شخص</u><u> </u></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات حساسية، بما في ذلك التورد والاحمرار، والطفح الجلدي، والنتوءات الجلدية المسببة للحكة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات حساسية خطيرة، بما في ذلك التأق (الضعف، انخفاض ضغط الدم، صعوبة التنفس، تورم الوجه).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة حجم الطحال (الطحال هو عضو يقع في منطقة البطن إلى يسار المعدة ويشترك في إنتاج خلايا الدم والتخلص منها ويشكل جزءًا من جهاز المناعة). أخبر طبيبك إذا لاحظت زيادة في حجم الجانب الأيسر العلوي من بطنك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تمزق الطحال، وهو أمر يمكن أن يكون مميتًا. من المهم أن تتصل بطبيبك على الفور إذا شعرت بألم في الجانب الأيسر العلوي من البطن أو ألم في الكتف الأيسر، حيث قد يرتبط ذلك بوجود مشكلة في الطحال.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلات في التنفس. إذا كنت تعاني من السعال والحمى وصعوبة التنفس، فأخبر طبيبك بذلك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; متلازمة سويت (آفات مؤلمة وبارزة أرجوانية اللون تظهر على الأطراف وفي بعض الأحيان على الوجه والرقبة تصحبها حمى).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الالتهاب الوعائي الجلدي (التهاب الأوعية الدموية في الجلد).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تلف في الكليتين (يسمى التهاب كبيبات الكلى).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احمرار في موضع الحقن.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السعال الدموي (بصق الدم).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات الدم (متلازمة خلل التنسج النقوي [MDS] أو ابيضاض الدم النخاعي الحاد [AML]).</p><p>&nbsp;</p><p dir="RTL"><u>نادرة: قد تصيب ما يصل إلى شخص واحد من بين كل ۱۰۰۰ شخص</u></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الشريان الأبهر (الوعاء الدموي الكبير الذي ينقل الدم من القلب إلى الجسم). انظر القسم ۲.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف من الرئة (النزف الرئوي).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; متلازمة ستيفنز-جونسون، يمكن أن تظهر في صورة بقع ضاربة إلى الحمرة تشبه دائرة التصويب أو بقع دائرية غالبًا ما توجد بثور في منتصفها تنتشر على الجذع، تقشر الجلد، قرح الفم والحلق والأنف والأعضاء التناسلية والعينين، وعلى الأرجح تكون مسبوقة بالحمى وأعراض شبيهة بأعراض الإنفلونزا. توقف عن استخدام نيفبريا إذا أصبت بهذه الأعراض واتصل بطبيبك أو اِسع للحصول على الرعاية الطبية على الفور. انظر أيضًا القسم ۲.</p><p>&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الأعراض الجانبية</strong><strong> </strong></p><p dir="RTL">إذا أصبت بأي أعراض جانبية، فتحدث إلى طبيبك أو الصيدلي أو الممرضة. يتضمن هذا أي أعراض جانبية محتملة غير مذكورة في هذه النشرة. بالإبلاغ عن الأعراض الجانبية، يمكنك المساعدة في توفير المزيد من المعلومات حول سلامة هذا الدواء.</p><p>&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الأعراض الجانبية</strong></p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>المملكة العربية السعودية:</strong></p><p><strong>&nbsp;</strong></p><table dir="rtl" border="1" cellspacing="0" cellpadding="0" style="width:408px"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><strong>المركز الوطني للتيقظ الدوائي:</strong></p><p dir="RTL">مركز الاتصال الموحد: ۱۹۹۹۹</p><p dir="RTL">البريد الإلكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">الموقع الإلكتروني: https://ade.sfda.gov.sa/&nbsp;&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>دول الخليج الأخرى</strong></p><p><strong>&nbsp;</strong></p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><em>-&nbsp;&nbsp;&nbsp; </em><em>الرجاء الاتصال بالمؤسسات والهيئات الوطنية في كل دولة.</em></p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احفظ هذا الدواء بعيدًا عن مرأى ومتناول الأطفال.</p><p>&nbsp;</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المكتوب على العلبة الكرتونية وعلى الملصق الخاص بالمحقنة بعد الرمز EXP. يشير تاريخ انتهاء الصلاحية إلى آخر يوم من الشهر المذكور.<br /><br />صلاحية المستحضر: <strong>٣</strong><strong> </strong>سنوات.</p><p>&nbsp;</p><p dir="RTL">خزنه في البراد (الثلاجة) (من درجتين مئويتين إلى ۸ درجات مئوية).</p><p>&nbsp;</p><p dir="RTL">يمكنك إخراج نيفبريا من البراد (الثلاجة) وتركه في درجة حرارة الغرفة (لا تزيد عن ۲٥ درجة مئوية) لمدة لا تتجاوز ۱٥ يومًا. بمجرد إخراج المحقنة من البراد (الثلاجة) ووصولها إلى درجة حرارة الغرفة (لا تزيد عن ۲٥ درجة مئوية)، يجب استخدامها في غضون ۱٥ يومًا أو التخلص منها.</p><p>&nbsp;</p><p dir="RTL">لا تقم بتجميده. يُسمح باستخدام نيفبريا إذا تم تجميده عن طريق الخطأ لفترة زمنية واحدة تقل عن ۲٤ ساعة.</p><p>&nbsp;</p><p dir="RTL">احتفظ بالحاوية في العلبة الكرتونية الخارجية لحمايتها من الضوء.</p><p>&nbsp;</p><p dir="RTL">لا تستخدم هذا الدواء إذا لاحظت أنه معكر أو يحتوي على جسيمات.</p><p>&nbsp;</p><p dir="RTL">لا تتخلص من أي أدوية عبر مياه الصرف أو مع النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستخدمها. ستساعد هذه الإجراءات على حماية البيئة.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعالة هي بيجفيلجراستيم. تحتوي كل محقنة مسبقة التعبئة على ٦ ملجم من بيجفيلجراستيم في ٦,۰ مل من المحلول.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي أسيتات الصوديوم ثلاثي الهيدرات، وحمض الخليك الجليدي، والسوربيتول ، والبولي سوربات ۲۰، وماء للحقن (انظر القسم ۲ &quot; يحتوي نيفبريا على السوربيتول وأسيتات الصوديوم&quot;).</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">نيفبريا هو محلول مخصص للحقن صافٍ وعديم اللون ويخلو من الجزيئات المرئية يأتي في محقنة مسبقة التعبئة (٦ ملجم/٦,۰ مل).</p><p>&nbsp;</p><p dir="RTL">تحتوي كل عبوة على محقنة زجاجية واحدة مسبقة التعبئة مرفق معها إبرة من الفولاذ المقاوم للصدأ وغطاء للإبرة وواقي إبرة أوتوماتيكي.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مالك رخصة التسويق</strong></p><p dir="RTL">Pfizer Europe MA EEIG</p><p dir="RTL">Boulevard de la Plaine 17</p><p dir="RTL">1050 Bruxelles</p><p dir="RTL">Belgium، بلجيكا</p><p>&nbsp;</p><p dir="RTL"><strong>جهة التصنيع</strong></p><p dir="RTL">Hospira Zagreb d.o.o.</p><p dir="RTL">Prudnička cesta 60</p><p dir="RTL">10291 Prigorje Brdovečko</p><p dir="RTL">Croatia، كرواتيا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            كتوبر ٢٠٢۱ 
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Nyvepria 6 mg solution for injection
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each pre filled syringe contains 6 mg of pegfilgrastim* in 0.6 mL solution for injection. The concentration is 10 mg/mL based on protein only**. 

*Produced in Escherichia coli cells by recombinant DNA technology followed by conjugation with polyethylene glycol (PEG). 
**The concentration is 20 mg/mL if the PEG moiety is included. 

The potency of this medicinal product should not be compared to the potency of another pegylated or non pegylated protein of the same therapeutic class. For more information, see section 5.1. 

Excipients with known effect 

Each pre filled syringe contains 30 mg sorbitol (see section 4.4). 

For the full list of excipients, see section 6.1. 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for injection (injection). 

Clear, colourless, free from visible particles, solution for injection. 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Nyvepria therapy should be initiated and supervised by physicians experienced in oncology and/or haematology.</p><p>&nbsp;</p><p><u>Posology</u></p><p>&nbsp;</p><p>One 6&nbsp;mg dose (a single pre‑filled syringe) of Nyvepria is recommended for each chemotherapy cycle, given at least 24&nbsp;hours after cytotoxic chemotherapy.</p><p>&nbsp;</p><p><u>Special populations</u></p><p>&nbsp;</p><p><em>Renal impairment</em></p><p>No dose change is recommended in patients with renal impairment, including those with end‑stage renal disease.</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>The safety and efficacy of pegfilgrastim in children and adolescents have not yet been established. Currently available data are described in sections&nbsp;4.8, 5.1 and 5.2 but no recommendation on a posology can be made.</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>&nbsp;</p><p>Nyvepria is injected subcutaneously.</p><p>&nbsp;</p><p>The injections should be given into the thigh, abdomen or upper arm.</p><p>&nbsp;</p><p>For instructions on handling of the medicinal product before administration, see section&nbsp;6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Traceability</u></p><p>&nbsp;</p><p>In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.</p><p>&nbsp;</p><p>Limited clinical data suggest a comparable effect on time to recovery of severe neutropenia for pegfilgrastim to filgrastim in patients with <em>de novo </em>acute myeloid leukaemia (AML) (see section&nbsp;5.1). However, the long‑term effects of pegfilgrastim have not been established in AML; therefore, it should be used with caution in this patient population.</p><p>&nbsp;</p><p>Granulocyte‑colony stimulating factor (G-CSF) can promote growth of myeloid cells <em>in vitro </em>and similar effects may be seen on some non‑myeloid cells <em>in vitro</em>.</p><p>&nbsp;</p><p>The safety and efficacy of pegfilgrastim have not been investigated in patients with myelodysplastic syndrome, chronic myelogenous leukaemia, and in patients with secondary AML; therefore, it should not be used in such patients. Particular care should be taken to distinguish the diagnosis of blast transformation of chronic myeloid leukaemia from AML.</p><p>&nbsp;</p><p>The safety and efficacy of pegfilgrastim administration in <em>de novo </em>AML patients aged &lt;&nbsp;55 years with cytogenetics t(15;17) have not been established.</p><p>&nbsp;</p><p>The safety and efficacy of pegfilgrastim have not been investigated in patients receiving high dose chemotherapy. This medicinal product should not be used to increase the dose of cytotoxic chemotherapy beyond established dose regimens.</p><p>&nbsp;</p><p><u>Pulmonary adverse events</u></p><p>&nbsp;</p><p>Pulmonary adverse reactions, in particular interstitial pneumonia, have been reported after G‑CSF administration. Patients with a recent history of pulmonary infiltrates or pneumonia may be at higher risk (see section&nbsp;4.8).</p><p>&nbsp;</p><p>The onset of pulmonary signs such as cough, fever, and dyspnoea in association with radiological signs of pulmonary infiltrates, and deterioration in pulmonary function along with increased neutrophil count may be preliminary signs of acute respiratory distress syndrome (ARDS). In such circumstances pegfilgrastim should be discontinued at the discretion of the physician and the appropriate treatment given (see section&nbsp;4.8).</p><p>&nbsp;</p><p><u>Glomerulonephritis </u></p><p>&nbsp;</p><p>Glomerulonephritis has been reported in patients receiving filgrastim and pegfilgrastim. Generally, events of glomerulonephritis resolved after dose reduction or withdrawal of filgrastim and pegfilgrastim. Urinalysis monitoring is recommended.</p><p>&nbsp;</p><p><u>Capillary leak syndrome</u></p><p>&nbsp;</p><p>Capillary leak syndrome has been reported after G‑CSF administration and is characterised by hypotension, hypoalbuminaemia, oedema and haemoconcentration. Patients who develop symptoms of capillary leak syndrome should be closely monitored and receive standard symptomatic treatment, which may include a need for intensive care (see section&nbsp;4.8).</p><p>&nbsp;</p><p><u>Splenomegaly and splenic rupture</u></p><p>&nbsp;</p><p>Generally asymptomatic cases of splenomegaly and cases of splenic rupture, including some fatal cases, have been reported following administration of pegfilgrastim (see section&nbsp;4.8). Therefore, spleen size should be carefully monitored (e.g. clinical examination, ultrasound). A diagnosis of splenic rupture should be considered in patients reporting left upper abdominal pain or shoulder tip pain.</p><p>&nbsp;</p><p><u>Thrombocytopenia and anaemia</u></p><p>&nbsp;</p><p>Treatment with pegfilgrastim alone does not preclude thrombocytopenia and anaemia because full dose myelosuppressive chemotherapy is maintained on the prescribed schedule. Regular monitoring of platelet count and haematocrit is recommended. Special care should be taken when administering single or combination chemotherapeutic agents which are known to cause severe thrombocytopenia.</p><p>&nbsp;</p><p><u>Myelodysplastic syndrome and acute myeloid leukaemia in breast and lung cancer patients</u></p><p>&nbsp;</p><p>In the post-marketing observational study setting, pegfilgrastim in conjunction with chemotherapy and/or radiotherapy has been associated with development of myelodysplastic syndrome (MDS) and acute myeloid leukaemia (AML) in breast and lung cancer patients (see section 4.8). Monitor breast and lung cancer patients for signs and symptoms of MDS/AML.</p><p>&nbsp;</p><p><u>Sickle cell anaemia</u></p><p>&nbsp;</p><p>Sickle cell crises have been associated with the use of pegfilgrastim in patients with sickle cell trait or sickle cell disease (see section 4.8). Therefore, physicians should use caution when prescribing pegfilgrastim in patients with sickle cell trait or sickle cell disease, should monitor appropriate clinical parameters and laboratory status and be attentive to the possible association of this medicinal product with splenic enlargement and vaso‑occlusive crisis.</p><p>&nbsp;</p><p><u>Leukocytosis</u></p><p>&nbsp;</p><p>White blood cell (WBC) counts of 100&times;10<sup>9</sup>/L or greater have been observed in less than 1% of patients receiving pegfilgrastim. No adverse events directly attributable to this degree of leukocytosis have been reported. Such elevation in white blood cells is transient, typically seen 24 to 48&nbsp;hours after administration and is consistent with the pharmacodynamic effects of this medicinal product. Consistent with the clinical effects and the potential for leukocytosis, a WBC count should be performed at regular intervals during therapy. If leukocyte counts exceed 50&times;10<sup>9</sup>/L after the expected nadir, this medicinal product should be discontinued immediately.</p><p>&nbsp;</p><p><u>Hypersensitivity</u></p><p>&nbsp;</p><p>Hypersensitivity, including anaphylactic reactions, occurring on initial or subsequent treatment, have been reported in patients treated with pegfilgrastim. Permanently discontinue pegfilgrastim in patients with clinically significant hypersensitivity. Do not administer pegfilgrastim to patients with a history of hypersensitivity to pegfilgrastim or filgrastim. If a serious allergic reaction occurs, appropriate therapy should be administered, with close patient follow‑up over several days.</p><p>&nbsp;</p><p><u>Stevens-Johnson syndrome</u></p><p>&nbsp;</p><p>Stevens-Johnson syndrome (SJS), which can be life-threatening or fatal, has been reported rarely in association with pegfilgrastim treatment. If the patient has developed SJS with the use of pegfilgrastim, treatment with pegfilgrastim must not be restarted in this patient at any time (see also section&nbsp;4.8).</p><p>&nbsp;</p><p><u>Immunogenicity</u></p><p>&nbsp;</p><p>As with all therapeutic proteins, there is a potential for immunogenicity. Rates of generation of antibodies against pegfilgrastim are generally low. Binding antibodies do occur as expected with all biologics; however, they have not been associated with neutralising activity at present.</p><p>&nbsp;</p><p><u>Aortitis</u></p><p><u>&nbsp;</u></p><p>Aortitis has been reported after G‑CSF administration in healthy subjects and in cancer patients. The symptoms experienced included fever, abdominal pain, malaise, back pain, and increased inflammatory markers (e.g. C‑reactive protein and WBC count). In most cases aortitis was diagnosed by computed tomography (CT) scan and generally resolved after withdrawal of G‑CSF (see also section&nbsp;4.8).</p><p>&nbsp;</p><p><u>Other warnings</u></p><p>&nbsp;</p><p>The safety and efficacy of pegfilgrastim for the mobilisation of blood progenitor cells in patients or healthy donors have not been adequately evaluated.</p><p>&nbsp;</p><p>Increased haematopoietic activity of the bone marrow in response to growth factor therapy has been associated with transient positive bone-imaging findings. This should be considered when interpreting bone‑imaging results.</p><p>&nbsp;</p><p><u>Sorbitol</u></p><p>&nbsp;</p><p>Nyvepria contains 30&nbsp;mg sorbitol in each pre-filled syringe which is equivalent to 50&nbsp;mg/mL. The additive effect of concomitantly administered medicinal products containing sorbitol (or fructose) and dietary intake of sorbitol (or fructose) should be taken into account.</p><p>&nbsp;</p><p><u>Sodium</u></p><p>&nbsp;</p><p>This medicinal product contains less than 1&nbsp;mmol sodium (23&nbsp;mg) per 6&nbsp;mg dose, that is to say essentially &lsquo;sodium‑free&rsquo;.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Due to the potential sensitivity of rapidly dividing myeloid cells to cytotoxic chemotherapy&sbquo; pegfilgrastim should be administered at least 24&nbsp;hours after administration of cytotoxic chemotherapy. In clinical studies, pegfilgrastim has been safely administered 14&nbsp;days before chemotherapy. Concomitant use of pegfilgrastim with any chemotherapy agent has not been evaluated in patients. In animal models concomitant administration of pegfilgrastim and 5‑fluorouracil (5‑FU) or other antimetabolites has been shown to potentiate myelosuppression.</p><p>&nbsp;</p><p>Possible interactions with other haematopoietic growth factors and cytokines have not been specifically investigated in clinical studies.</p><p>&nbsp;</p><p>The potential for interaction with lithium, which also promotes the release of neutrophils, has not been specifically investigated. There is no evidence that such an interaction would be harmful.</p><p>&nbsp;</p><p>The safety and efficacy of pegfilgrastim have not been evaluated in patients receiving chemotherapy associated with delayed myelosuppression e.g. nitrosoureas.</p><p>&nbsp;</p><p>Specific interaction or metabolism studies have not been performed, however, clinical studies have not indicated an interaction of pegfilgrastim with any other medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>&nbsp;</p><p>There are no or limited amount of data from the use of pegfilgrastim in pregnant women. Studies in animals have shown reproductive toxicity (see section&nbsp;5.3). Pegfilgrastim is not recommended during pregnancy and in women of childbearing potential not using contraception.</p><p>&nbsp;</p><p><u>Breast‑feeding</u></p><p>&nbsp;</p><p>There is insufficient information on the excretion of pegfilgrastim/metabolites in human milk. A risk to the newborns/infants cannot be excluded. A decision must be made whether to discontinue breast‑feeding or to discontinue/abstain from pegfilgrastim therapy taking into account the benefit of breast‑feeding for the child and the benefit of therapy for the woman.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>&nbsp;</p><p>Pegfilgrastim did not affect reproductive performance or fertility in male or female rats at cumulative weekly doses approximately 6 to 9&nbsp;times higher than the recommended human dose (based on body surface area) (see section&nbsp;5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Nyvepria has no or negligible influence on the ability to drive and use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>&nbsp;</p><p>The most frequently reported adverse reactions were bone pain (very common [&ge;1/10]) and musculoskeletal pain (common [&ge;1/100 to ˂1/10]). Bone pain was generally of mild to moderate severity, transient, and could be controlled in most patients with standard analgesics.</p><p>&nbsp;</p><p>Hypersensitivity‑type reactions, including skin rash, urticaria, angioedema, dyspnoea, erythema, flushing, and hypotension occurred on initial or subsequent treatment with pegfilgrastim (uncommon [&ge;1/1,000 to &lt;1/100]). Serious allergic reactions, including anaphylaxis can occur in patients receiving pegfilgrastim (uncommon) (see section&nbsp;4.4).</p><p>&nbsp;</p><p>Capillary leak syndrome, which can be life‑threatening if treatment is delayed, has been reported as uncommon (&ge;1/1,000 to &lt;1/100) in cancer patients undergoing chemotherapy following administration of G‑CSFs; see section&nbsp;4.4 and section &ldquo;Description of selected adverse reactions&rdquo; below.</p><p>&nbsp;</p><p>Splenomegaly, generally asymptomatic, is uncommon.</p><p>&nbsp;</p><p>Splenic rupture including some fatal cases is uncommonly reported following administration of pegfilgrastim (see section&nbsp;4.4).</p><p>&nbsp;</p><p>Uncommon pulmonary adverse reactions including interstitial pneumonia, pulmonary oedema, pulmonary infiltrates and pulmonary fibrosis have been reported. Uncommonly, cases have resulted in respiratory failure or ARDS, which may be fatal (see section&nbsp;4.4).</p><p>&nbsp;</p><p>Isolated cases of sickle cell crises have been reported in patients with sickle cell trait or sickle cell disease (uncommon in sickle cell patients) (see section 4.4).</p><p><u>&nbsp;</u></p><p><u>Tabulated list of adverse reactions</u></p><p>&nbsp;</p><p>The data in the table below describe adverse reactions reported from clinical studies and spontaneous reporting. Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td rowspan="2" style="vertical-align:top"><p><strong>MedDRA system organ class</strong></p></td><td colspan="4" style="vertical-align:top"><p><strong>Adverse reactions</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Very common</strong></p><p><strong>(&ge;1/10)</strong></p></td><td style="vertical-align:top"><p><strong>Common</strong></p><p><strong>(&ge;1/100 to &lt;1/10)</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p><p><strong>(&ge;1/1,000 to &lt;1/100)</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Rare</strong></p><p><strong>(&ge;1/10,000 to &lt;1/1,000)</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p><strong>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Myelodysplastic syndrome<sup>1</sup>;</p><p>Acute myeloid leukaemia<sup>1</sup></p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Thrombocytopenia<sup>1</sup>;</p><p>Leukocytosis<sup>1</sup></p></td><td style="vertical-align:top"><p>Sickle cell anaemia with crisis<sup>2</sup>;</p><p>Splenomegaly<sup>2</sup>;</p><p>Splenic rupture<sup>2</sup></p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hypersensitivity reactions;</p><p>Anaphylaxis</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Elevations in uric acid</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td><td style="vertical-align:top"><p>Headache<sup>1</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Capillary leak syndrome<sup>1</sup></p></td><td colspan="2" style="vertical-align:top"><p>Aortitis</p></td></tr><tr><td style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Acute respiratory distress syndrome<sup>2</sup>;</p><p>Pulmonary adverse reactions (interstitial pneumonia, pulmonary oedema, pulmonary infiltrates and pulmonary fibrosis);</p><p>Haemoptysis</p></td><td colspan="2" style="vertical-align:top"><p>Pulmonary haemorrhage</p></td></tr><tr><td style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td><td style="vertical-align:top"><p>Nausea<sup>1</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Sweet&rsquo;s syndrome (acute febrile neutrophilic dermatosis)<sup>1,2</sup>;</p><p>Cutaneous vasculitis<sup>1,2</sup></p></td><td colspan="2" style="vertical-align:top"><p>Stevens-Johnson syndrome</p></td></tr><tr><td style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td><td style="vertical-align:top"><p>Bone pain</p></td><td style="vertical-align:top"><p>Musculoskeletal pain (myalgia, arthralgia, pain in extremity, back pain, musculoskeletal pain, neck pain)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Renal and urinary disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Glomerulonephritis<sup>2</sup></p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>General disorders and administrative site conditions</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Injection site pain<sup>1</sup>;</p><p>Non‑cardiac chest pain</p></td><td style="vertical-align:top"><p>Injection site reactions<sup>2</sup></p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Investigations</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Elevations in lactate dehydrogenase and alkaline phosphatase<sup>1</sup>;</p><p>Transient elevations in LFTs for ALT or AST<sup>1</sup></p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p><sup>1 </sup>See section &ldquo;Description of selected adverse reactions&rdquo; below.</p><p><sup>2 </sup>This adverse reaction was identified through post‑marketing surveillance but not observed in randomised, controlled clinical studies in adults. The frequency category was estimated from a statistical calculation based upon 1,576&nbsp;patients receiving pegfilgrastim in nine randomised clinical studies.</p><p>&nbsp;</p><p><u>Description of selected adverse reactions</u></p><p>&nbsp;</p><p>Uncommon cases of Sweet&rsquo;s syndrome have been reported, although in some cases underlying haematological malignancies may play a role.</p><p>&nbsp;</p><p>Uncommon events of cutaneous vasculitis have been reported in patients treated with pegfilgrastim. The mechanism of vasculitis in patients receiving pegfilgrastim is unknown.</p><p>&nbsp;</p><p>Injection site reactions, including injection site erythema (uncommon) as well as injection site pain (common) have occurred on initial or subsequent treatment with pegfilgrastim.</p><p>&nbsp;</p><p>Common cases of leukocytosis (WBC&nbsp;&gt;100&times;10<sup>9</sup>/L) have been reported (see section&nbsp;4.4).</p><p>&nbsp;</p><p>Reversible, mild to moderate elevations in uric acid and alkaline phosphatase, with no associated clinical effects, were uncommon; reversible, mild to moderate elevations in lactate dehydrogenase, with no associated clinical effects, were uncommon in patients receiving pegfilgrastim following cytotoxic chemotherapy.</p><p>&nbsp;</p><p>Nausea and headaches were very commonly observed in patients receiving chemotherapy.</p><p>&nbsp;</p><p>Uncommon elevations in liver function tests (LFTs) for alanine aminotransferase (ALT) or aspartate aminotransferase (AST), have been observed in patients after receiving pegfilgrastim following cytotoxic chemotherapy. These elevations are transient and return to baseline.</p><p>&nbsp;</p><p>An increased risk of MDS/AML following treatment with pegfilgrastim in conjunction with chemotherapy and/or radiotherapy has been observed in an epidemiological study in breast and lung cancer patients (see section 4.4).</p><p>&nbsp;</p><p>Common cases of thrombocytopenia have been reported.</p><p>&nbsp;</p><p>Cases of capillary leak syndrome have been reported in the post‑marketing setting with G‑CSF use. These have generally occurred in patients with advanced malignant diseases, sepsis, taking multiple chemotherapy medications or undergoing apheresis (see section&nbsp;4.4).</p><p><u>&nbsp;</u></p><p><u>Paediatric population</u></p><p>&nbsp;</p><p>The experience in children is limited. A higher frequency of serious adverse reactions in younger children aged 0‑5 years (92%) has been observed compared to older children aged 6‑11 and 12‑21&nbsp;years respectively (80% and 67%) and adults. The most common adverse reaction reported was bone pain (see sections&nbsp;5.1 and 5.2).</p><p><u>&nbsp;</u></p><p><u>Reporting of suspected adverse reactions</u></p><p>&nbsp;</p><p>Reporting suspected adverse reactions after marketing authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions to National Pharmacovigilance Center (NPC).</p><p><strong>&nbsp;</strong></p><p><strong>To Report side effects</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia:</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:408px"><tbody><tr><td style="vertical-align:top"><p><strong>National Pharmacovigilance Center (NPC)</strong></p><p>SFDA Call center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa/&nbsp;&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other GCC States</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp; <em>Please contact the relevant competent authority.</em></p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Single doses of 300&nbsp;mcg/kg have been administered subcutaneously to a limited number of healthy volunteers and patients with non‑small cell lung cancer without serious adverse reactions. The adverse events were similar to those in subjects receiving lower doses of pegfilgrastim<em>. </em></p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: immunostimulants, colony stimulating factors; ATC Code: L03AA13.</p><p>&nbsp;</p><p>Nyvepria is a biosimilar medicinal product.</p><p>&nbsp;</p><p>Human G‑CSF is a glycoprotein, which regulates the production and release of neutrophils from the bone marrow. Pegfilgrastim is a covalent conjugate of recombinant human G‑CSF (r‑metHuG‑CSF) with a single 20 kd PEG molecule. Pegfilgrastim is a sustained duration form of filgrastim due to decreased renal clearance. Pegfilgrastim and filgrastim have been shown to have identical modes of action, causing a marked increase in peripheral blood neutrophil counts within 24&nbsp;hours, with minor increases in monocytes and/or lymphocytes. Similarly to filgrastim, neutrophils produced in response to pegfilgrastim show normal or enhanced function as demonstrated by tests of chemotactic and phagocytic function. As with other haematopoietic growth factors, G‑CSF has shown <em>in vitro</em> stimulating properties on human endothelial cells. G‑CSF can promote growth of myeloid cells, including malignant cells, <em>in vitro </em>and similar effects may be seen on some non‑myeloid cells <em>in vitro</em>.</p><p>&nbsp;</p><p>In two randomised, double‑blind, pivotal studies in patients with high‑risk stage II‑IV breast cancer undergoing myelosuppressive chemotherapy consisting of doxorubicin and docetaxel, use of pegfilgrastim, as a single once per cycle dose, reduced the duration of neutropenia and the incidence of febrile neutropenia similarly to that observed with daily administrations of filgrastim (a median of 11&nbsp;daily administrations). In the absence of growth factor support, this regimen has been reported to result in a mean duration of grade&nbsp;4 neutropenia of 5 to 7&nbsp;days, and a 30‑40% incidence of febrile neutropenia. In one study (n=157), which used a 6&nbsp;mg fixed dose of pegfilgrastim the mean duration of grade&nbsp;4 neutropenia for the pegfilgrastim group was 1.8&nbsp;days compared with 1.6&nbsp;days in the filgrastim group (difference 0.23&nbsp;days, 95% CI ‑0.15, 0.63). Over the entire study, the rate of febrile neutropenia was&nbsp;13% of pegfilgrastim‑treated patients compared with 20% of filgrastim‑treated patients (difference 7%, 95% CI of ‑19%, 5%). In a second study (n=310), which used a weight‑adjusted dose (100&nbsp;mcg/kg), the mean duration of grade&nbsp;4 neutropenia for the pegfilgrastim group was 1.7&nbsp;days, compared with 1.8&nbsp;days in the filgrastim group (difference 0.03&nbsp;days, 95%&nbsp;CI ‑0.36, 0.30). The overall rate of febrile neutropenia was 9% of patients treated with pegfilgrastim and 18% of patients treated with filgrastim (difference 9%, 95% CI of ‑16.8%, ‑1.1%).</p><p>&nbsp;</p><p>In a placebo‑controlled, double‑blind study in patients with breast cancer the effect of pegfilgrastim on the incidence of febrile neutropenia was evaluated following administration of a chemotherapy regimen associated with a febrile neutropenia rate of 10‑20% (docetaxel 100&nbsp;mg/m<sup>2 </sup>every 3&nbsp;weeks for 4&nbsp;cycles). Nine hundred and twenty-eight&nbsp;patients were randomised to receive either a single dose of pegfilgrastim or placebo approximately 24&nbsp;hours (day&nbsp;2) after chemotherapy in each cycle. The incidence of febrile neutropenia was lower for patients randomised to receive pegfilgrastim compared with placebo (1% versus 17%, p &lt;&nbsp;0.001). The incidence of hospitalisations and IV anti‑infective use associated with a clinical diagnosis of febrile neutropenia was lower in the pegfilgrastim group compared with placebo (1% versus 14%, p&nbsp;&lt;0.001; and 2% versus 10%, p&nbsp;&lt;0.001).</p><p>&nbsp;</p><p>A small (n=83), phase&nbsp;II, randomised, double‑blind study in patients receiving chemotherapy for <em>de&nbsp;novo </em>acute myeloid leukaemia compared pegfilgrastim (single dose of 6&nbsp;mg) with filgrastim, administered during induction chemotherapy. Median time to recovery from severe neutropenia was estimated as 22&nbsp;days in both treatment groups. Long‑term outcome was not studied (see section&nbsp;4.4).</p><p>&nbsp;</p><p>In a phase&nbsp;II (n=37) multicentre, randomised, open‑label study of paediatric sarcoma patients receiving 100&nbsp;mcg/kg pegfilgrastim following cycle&nbsp;1 of vincristine, doxorubicin and cyclophosphamide (VAdriaC/IE) chemotherapy, a longer duration of severe neutropenia (neutrophils &lt;0.5&times;10<sup>9</sup>/L) was observed in younger children aged 0‑5&nbsp;years (8.9&nbsp;days) compared to older children aged 6‑11&nbsp;years and 12‑21&nbsp;years (6&nbsp;days and 3.7&nbsp;days, respectively) and adults. Additionally a higher incidence of febrile neutropenia was observed in younger children aged 0‑5&nbsp;years (75%) compared to older children aged 6‑11&nbsp;years and 12‑21&nbsp;years (70% and 33%, respectively) and adults (see sections&nbsp;4.8 and 5.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>After a single subcutaneous dose of pegfilgrastim, the peak serum concentration of pegfilgrastim occurs at 16 to 120&nbsp;hours after dosing and serum concentrations of pegfilgrastim are maintained during the period of neutropenia after myelosuppressive chemotherapy. The elimination of pegfilgrastim is non-linear with respect to dose; serum clearance of pegfilgrastim decreases with increasing dose. Pegfilgrastim appears to be mainly eliminated by neutrophil‑mediated clearance, which becomes saturated at higher doses. Consistent with a self-regulating clearance mechanism, the serum concentration of pegfilgrastim declines rapidly at the onset of neutrophil recovery (see figure&nbsp;1).</p><p>&nbsp;</p><p><strong>Figure 1. Profile of median pegfilgrastim serum concentration and absolute neutrophil count (ANC) in chemotherapy treated patients after a single 6&nbsp;mg injection</strong></p><p>&nbsp;</p><p><!--[if gte vml 1]><v:shapetype id="_x0000_t75"
 coordsize="21600,21600" o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe"
 filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Picture_x0020_1" o:spid="_x0000_i1025" type="#_x0000_t75"
 style='width:358.5pt;height:223.5pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
</v:shape><![endif]--><img width="478" height="298" src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image002.jpg" /></p><p>&nbsp;</p><p>Due to the neutrophil‑mediated clearance mechanism, the pharmacokinetics of pegfilgrastim is not expected to be affected by renal or hepatic impairment. In an open‑label, single dose study (n=31) various stages of renal impairment, including end‑stage renal disease, had no impact on the pharmacokinetics of pegfilgrastim.</p><p>&nbsp;</p><p><u>Elderly</u></p><p>&nbsp;</p><p>Limited data indicate that the pharmacokinetics of pegfilgrastim in elderly subjects (&gt;&nbsp;65 years) is similar to that in adults.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>&nbsp;</p><p>The pharmacokinetics of pegfilgrastim was studied in 37&nbsp;paediatric patients with sarcoma, who received 100&nbsp;mcg/kg pegfilgrastim after the completion of VAdriaC/IE chemotherapy. The youngest age group (0‑5&nbsp;years) had a higher mean exposure to pegfilgrastim (AUC) (&plusmn; standard deviation) (47.9 &plusmn; 22.5 mcg&middot;hr/mL) than older children aged 6‑11&nbsp;years and 12‑21&nbsp;years (22.0 &plusmn; 13.1 mcg&middot;hr/mL and 29.3 &plusmn; 23.2 mcg&middot;hr/mL, respectively) (see section&nbsp;5.1). With the exception of the youngest age group (0‑5&nbsp;years), the mean AUC in paediatric subjects appeared similar to that for adult patients with high‑risk stage&nbsp;II‑IV breast cancer and receiving 100&nbsp;mcg/kg pegfilgrastim after the completion of doxorubicin/docetaxel (see sections&nbsp;4.8 and 5.1).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Preclinical data from conventional studies of repeated dose toxicity revealed the expected pharmacological effects including increases in leukocyte count, myeloid hyperplasia in bone marrow, extramedullary haematopoiesis and splenic enlargement.</p><p>&nbsp;</p><p>There were no adverse effects observed in offspring from pregnant rats given pegfilgrastim subcutaneously, but in rabbits pegfilgrastim has been shown to cause embryo/foetal toxicity (embryo loss) at cumulative doses approximately 4&nbsp;times the recommended human dose, which were not seen when pregnant rabbits were exposed to the recommended human dose. In rat studies, it was shown that pegfilgrastim may cross the placenta. Studies in rats indicated that reproductive performance, fertility, oestrous cycling, days between pairing and coitus, and intrauterine survival were unaffected by pegfilgrastim given subcutaneously. The relevance of these findings for humans is not known.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sodium acetate trihydrate</p><p>Glacial acetic acid</p><p>Sorbitol</p><p>Polysorbate&nbsp;20</p><p>Water for injections</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product must not be mixed with other medicinal products, particularly with sodium chloride solutions.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years. 

Do not use Nyvepria medicine after the expiry date which is stated on the carton and on the syringe label after EXP. The expiry date refers to the last day of that month. 

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in a refrigerator (2&deg;C&nbsp;&ndash;&nbsp;8&deg;C).</p><p>&nbsp;</p><p>Nyvepria may be exposed to room temperature (not above 25&deg;C) for a maximum single period of up to 15&nbsp;days. Nyvepria left at room temperature for more than 15&nbsp;days should be discarded.</p><p>&nbsp;</p><p>Do not freeze. Accidental exposure to freezing temperatures for a single period of less than 24&nbsp;hours does not adversely affect the stability of Nyvepria.</p><p>&nbsp;</p><p>Keep the container in the outer carton in order to protect from light.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pre‑filled syringe (type&nbsp;I glass), with a rubber stopper, stainless steel needle and needle cover with an automatic needle guard. The Nyvepria syringe plunger stopper and needle cover are not made with natural rubber latex.</p><p>&nbsp;</p><p>Each pre‑filled syringe contains 0.6&nbsp;mL of solution for injection.</p><p>&nbsp;</p><p>Pack size of one&nbsp;pre‑filled syringe, in a carton.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Before use, Nyvepria solution should be inspected visually for particulate matter. Only a solution that is clear and colourless should be injected.</p><p>&nbsp;</p><p>Excessive shaking may aggregate pegfilgrastim, rendering it biologically inactive.</p><p>&nbsp;</p><p>Allow the pre‑filled syringe to come to room temperature for 30 minutes before using the syringe.</p><p>&nbsp;</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p><p>&nbsp;</p><p>Keep out of the sight and reach of children.</p><p>&nbsp;</p><p>Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Pfizer Europe MA EEIG
Boulevard de la Plaine 17
1050 Bruxelles
Belgium

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                October 2021
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>